✦ LIBER ✦

Overlap syndrome of polymyositis and progressive systemic sclerosis associated with interferon therapy for chronic hepatitis C

✍ Scribed by Otsuka, Takeshi ;Sakamoto, Noriko ;Tanaka, Yosuke ;Yamaoka, Kunihiro ;Nakashima, Hitoshi ;Yoshizawa, Shigeru ;Horiuchi, Takahiko ;Niho, Yoshiyuki

Publisher: Informa UK (Informa Healthcare)
Year: 1999
Tongue: English
Weight: 793 KB
Volume: 9
Category: Article
ISSN: 0169-1163
DOI: 10.1007/bf03041283

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Analysis of clinical and virological fac

Analysis of clinical and virological factors associated with response to alpha interferon therapy in chronic hepatitis C

✍ Dr. J. A. Garson; K. Whitby; R. Deaville; S. Brillanti; M. Foli; C. Masci; M. Mi 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 508 KB

## Abstract Interferon alpha (IFN‐α) therapy is currently the treatment of choice for chronic hepatitis C (HCV) infection, but it fails to achieve a sustained response in approximately 75% of those treated. The factors which determine whether or not an individual will respond to IFN‐α are uncertain

Limitation of combination therapy of int

Limitation of combination therapy of interferon and ribavirin for older patients with chronic hepatitis C

✍ Yoshiaki Iwasaki; Hiroshi Ikeda; Yasuyuki Araki; Toshiya Osawa; Keiji Kita; Masa 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 187 KB 👁 2 views

In contrast to the United States, Japanese patients with chronic hepatitis C currently treated with interferon are generally 10 to 15 years older. Older patients, however, tend to experience more frequent adverse events. This study was conducted to clarify the effect of patient age on the efficacy a

Prospective study of interferon therapy

Prospective study of interferon therapy for compensated cirrhotic patients with chronic hepatitis C by monitoring serum hepatitis C RNA

✍ Yasushi Shiratori; Osamu Yokosuka; Ryo Nakata; Masashi Ihori; Katsutaro Hirota; 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 146 KB 👁 2 views

Because interferon therapy exhibits low efficacy for cirrhotic patients infected with hepatitis C virus, this prospective study was conducted to determine effective interferon regimens tailored to treatment response by monitoring HCV RNA status. A total of 157 cirrhotic patients were enrolled to rec

Efficacy of prolonged interferon therapy

Efficacy of prolonged interferon therapy for patients with chronic hepatitis C with HCV-genotype 1b and high virus load

✍ Yasuji Arase; Kenji Ikeda; Akihito Tsubota; Yoshiyuki Suzuki; Satoshi Saitoh; Ma 📂 Article 📅 2003 🏛 Springer Japan 🌐 English ⚖ 163 KB

Adequate timing of ribavirin reduction i

Adequate timing of ribavirin reduction in patients with hemolysis during combination therapy of interferon and ribavirin for chronic hepatitis C

✍ Yasuji Arase; Kenji Ikeda; Fumitaka Suzuki; Yoshiyuki Suzuki; Satoshi Saitoh; Ma 📂 Article 📅 2004 🏛 Springer Japan 🌐 English ⚖ 171 KB

A mutation in the interferon sensitivity

A mutation in the interferon sensitivity-determining region is associated with responsiveness to interferon-ribavirin combination therapy in chronic hepatitis patients infected with a Japan-specific subtype of hepatitis C virus genotype 1b

✍ Mutsumi Murayama; Yoshiaki Katano; Isao Nakano; Masatoshi Ishigami; Kazuhiko Hay 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 178 KB 👁 2 views

## Abstract The interferon sensitivity‐determining region (ISDR) is useful as a predictive marker of the response to interferon (IFN) therapy for chronic hepatitis patients with a Japan‐specific subtype (J‐type) of hepatitis C virus (HCV) genotype 1b. This marker is not useful for predicting respon